Podcasts about biopharma

In this episode of the GSD Presents Silicon Valley AI & Tech series, we sit down with the visionary founders of Matrix Edge Therapeutics, Elaine Phan and Andreas Taylor.We dive deep into how they are building the "Signal → Cure → Longevity" AI infrastructure to revolutionize drug discovery and patient stratification. Learn how continuous patient signals and agentic AI are being used to reduce clinical trial-and-error, speed up cure development, and ultimately extend human healthspan.Key Topics Covered:The shift from reactive medicine to AI-driven Precision Medicine.How "Continuous Patient Signals" improve subtyping and stratification.The role of AI in streamlining the lifecycle from drug discovery to post-market management.The future of longevity and bio-tech innovation.About the Guests:Elaine Phan: Founder of Matrix Edge Therapeutics, Biopharma leader (20+ years), NIH AI strategist, and UC Berkeley/Stanford/Georgia Tech alumna.Andreas Taylor: Co-Founder & CTO, Genentech veteran, Data Scientist, and expert in agentic AI applications and drug delivery.Connect with GSD Venture Studios: gsdvs.com#PrecisionMedicine #AIinHealthcare #Longevity #DrugDiscovery #Biotech #GSDVS #TopGlobalStartups #HealthTech #BioPharma

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of breakthroughs and strategic maneuvers that are reshaping the landscape of this dynamic industry.Roche is making waves with its antibody Gazyva, initially recognized for cancer treatment. The company has successfully ventured into autoimmune diseases, targeting kidney conditions. Recent phase 3 trials have reinforced Gazyva's efficacy in treating immune-mediated kidney diseases, building on its prior approval for lupus nephritis. This marks a potential paradigm shift from oncology to autoimmune therapy applications, offering a promising new avenue for treating complex kidney disorders. Such advancements underscore the power of immune modulation in addressing severe health conditions.Turning to oncology, Eli Lilly is expanding the use of its cancer drug, Retevmo. Originally approved for specific lung and thyroid cancers with rare biomarkers, Lilly is now exploring its use in the adjuvant setting for non-small cell lung cancer. This effort reflects a broader trend in oncology: companies are increasingly looking to extend the application of targeted therapies beyond their initial indications. This expansion could significantly enhance treatment options and improve patient outcomes.In ophthalmology, Ocular Therapeutix is preparing for an FDA filing following positive phase 3 results for its wet age-related macular degeneration treatment. Their candidate, AXPAXLI, showed superior efficacy compared to Regeneron's Eylea in head-to-head trials. Despite investor skepticism, Ocular remains confident in its product's potential to impact retinal disease management positively. The competitive landscape in ophthalmology is fierce, and innovative treatments with substantial clinical benefits over existing therapies can redefine standards of care.Eli Lilly is also strategically stockpiling Orforglipron, its oral GLP-1 candidate, in anticipation of FDA approval for obesity treatment. This proactive measure aims to prevent supply chain issues seen during previous GLP-1 launches. It reflects an industry-wide focus on ensuring product availability at launch to meet growing market demand effectively.On the regulatory front, there are significant shifts as well. The Trump administration's renewed pilot of 340B rebates aims to optimize drug pricing frameworks. Novartis has secured a long-term supply agreement with Niowave for Actinium-225 (Ac-225), crucial for developing targeted cancer therapies. This highlights the sustained demand for radiopharmaceutical isotopes as part of precision medicine initiatives.Biopharma funding is expected to recover steadily by 2026, albeit with a cautious approach favoring de-risked assets over broader platform technologies. Venture capitalists prefer predictable returns amidst an evolving market landscape.Now, let's turn to Japan, where Innovacell is planning a $92 million IPO on the Tokyo Stock Exchange. This move signals a renewed interest in biotech within the region after a long drought in IPOs. Financial strategies like these are vital for advancing cell therapies that hold promise for treating conditions once deemed challenging.Gilead Sciences has acquired synthetic lethal therapy from Genhouse Bio through a $1.5 billion deal, further underscoring the growing interest in synthetic lethality as a novel cancer treatment approach. This strategy focuses on targeting tumors while sparing normal cells, offering more effective therapies with fewer side effects.In mental health innovations, Compass Pathways has reported positive results from its pivotal trial using psilocybin for treatment-resistant depression. The success of this phase 3 trial highlights the potential role of psychedelics in psychiatric care and could revolutionize mental health treatments by providing new options Support the show

What if cancer could be turned from a killer into a manageable chronic illness with no hair loss, no nausea, and no immunosuppression? In this gripping episode of Startup to Stock Exchange, host Seth Farbman goes deep with James Nathanielsz, CEO of NASDAQ-listed Propanc Biopharma (PPCB). From a 17-year grind raising over $30M, battling economic crashes, COVID, and regulatory wars, to compassionate-use stories where terminal patients defied odds and lived years longer, James reveals the science behind their novel proenzyme therapy PRP. Now NASDAQ-uplisted and gearing up for a landmark Phase 1b first-in-human trial in 2026 targeting advanced solid tumors like pancreatic and ovarian cancers, this could redefine treatment in massive markets. A raw, no-BS conversation on biotech perseverance, integrity in public markets, patient hope, and a potential game-changer that started with one doctor's desperate fight to save lives. Don't miss the underdog story that might just change everything.Seth's CompaniesVstock Transfer – https://www.vstocktransfer.com/Share Media – https://www.sharemedia.co/Listen to the ShowApple Podcasts – https://podcasts.apple.com/us/podcast/seth-farbman-on-podcast-from-startup-to-stock-exchange/id1356667808Spotify – https://open.spotify.com/show/54i7xkWaAALAFrUvk4WZcNConnect with SethLinkedIn – https://www.linkedin.com/in/sethfarbman/Instagram – https://www.instagram.com/sethfarbmanstockTikTok – https://www.tiktok.com/@sethfarbmanTwitter (X) – https://x.com/sethfarbman1About the ShowFrom Startup to Stock Exchange, hosted by entrepreneur and investor Seth Farbman, spotlights the journey of founders and CEOs as they scale their companies from early ideas to public markets. Each episode features candid conversations with leaders across industries, offering insights on growth, fundraising, branding, and the mindset it takes to build a company that lasts.00:48 – Seth introduces James Nathanielsz & Propanc Biopharma (PPCB)02:13 – Rambo scars analogy: 17+ years of entrepreneurial wars03:08 – Propanc today: 17 years, $30M raised, NASDAQ uplist 202503:55 – Seth on the insane conviction needed for 17-year biotech grind08:12 – Core motivation: helping families, belief the drug truly works10:37 – Origin: 28-year-old mom gained 2 extra years via treatment12:34 – 46 compassionate patients: 19 terminal cases beat huge odds, no side effects15:26 – Vision: Turn metastatic cancer into a chronic illness game-changing17:23 – “25 years of overnight success” 32:50 – Get treatment to patients fast, transformative potentialConnect with Seth LinkedIn – https://www.linkedin.com/in/sethfarbman/ Instagram – https://www.instagram.com/sethfarbmanstock TikTok – https://www.tiktok.com/@sethfarbman Twitter (X) – https://x.com/sethfarbman1

Renée Aguiar-Lucander, CEO of Hansa Biopharma, discussed the company's leading asset, its journey toward US FDA approval and the trials and tribulations of completing a Phase III program.

In this week’s episode of “The Top Line,” Fierce checks in with professional services juggernaut KPMG on the biopharma rebound many industry watchers predicted in the closing months of 2025. Fierce Pharma’s Fraiser Kansteiner sits down with Kristin Cirello Pothier, principal and U.S. and Americas region life sciences sector leader, as well as global deal advisory and strategy leader for health and life sciences at KPMG, to discuss the firm’s latest industry outlook. Pothier also explains how drugmakers are cutting through the noise and reflects on the technology, indication and valuation factors shaping today’s dealmaking appetite. To learn more about the topics in this episode: 2026 forecast: After a surge of M&A in Q4, will the trend continue? Halozyme catches M&A wave to snap up Surf Bio in delivery tech deal worth up to $400M Global pharma manufacturing output surged in '25 in 'front-loading' response to US tariff threats: report In quick reversal, Trump calls off tariff threat related to Greenland pursuit See omnystudio.com/listener for privacy information.

As biopharma pipelines grow more complex, manufacturers are under increasing pressure to scale faster, adapt to new modalities, and build resilience into highly regulated operations. Meeting these demands means manufacturing agility is no longer just a competitive advantage, it's a necessity. Yet, structural constraints, talent shortages, and legacy processes continue to impact progress across the industry. In this episode of Off Script, we spoke with Iwan Roberts, vice president of technology and innovation strategy at Cytiva, for a deep dive into Cytiva's latest Global Biopharma Index. The conversation explores why manufacturing agility remains a major industry pain point, why modalities like cell and gene therapy and mRNA are uniquely difficult to scale, and how CDMOs, digitalization, and new supplier relationships are reshaping the path forward.  

Today, we're thrilled to have Tim Opler, a leading voice in biotech investment banking. Tim's career spans academia, Credit Suisse, and co-founding Torreya Partners, which Stifel acquired in 2023. As Managing Director in Stifel's Global Healthcare Group, he's advised on over 150 deals totaling more than $100 billion, shaping major M&A, licensing, and financings in life sciences.Tim is renowned for his insightful Biopharma Market Updates, and in this episode, we'll dive into his December 2025 edition, where he outlines five transformative trends set to drive biopharma for the next decade: M&A booms, giant markets like obesity and aging drugs, China's rising innovation, AI's reshape of healthcare, and incredible scientific advances.01:22 - Meet Tim Opler03:12 - Stifel and the Biopharma Market Updates05:50 - Trend 1: M&A Booms10:06 - Trend 2: Giant Markets17:05 - Trend 3: China's Innovation22:29 - Trend 4: AI Reshaping Healthcare28:42 - Trend 5: Incredible Science34:18 - Looking forwardInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: 10 biotech companies in China you should know aboutWhen AI isn't enough: How physics is shaping the next wave of drug discovery JPM 2026: what's the outlook like this year? 

During the Asia-focused Episode 33 of Biotalk, Geoff Meyerson, CEO of Locust Walk, reviews key 2025 Year-In-Review trends across China, Japan, and Korea. China: Led global licensing (~48% share) with larger average deal sizes than the U.S. Public markets outperformed and Q4 IPO activity rebounded. Venture financing held steady, with out-licensing cemented as the dominant business model alongside more creative deal structures and cross-border activity. Japan: The Nikkei hit record highs and biotech momentum improved. Licensing rose to 13 deals across all development stages. Venture financing doubled, skewing early-stage, with strength in GI and renewed interest in cell therapy. Korea: Broader markets reached record highs, but biotech lagged. Venture financing rose meaningfully (40% volume, 60% value), focused on mid- to late-stage assets, especially oncology and protein degradation. Regional Takeaway: 2025 marked a turning point for Asia-Pacific biotech: China drove deal value and listings, Japan revitalized early-stage innovation, and Korea showed a cautious rebound as capital markets continued to thaw. Listen now to gain insights into the evolving global biopharma landscape, explore our report, and we welcome the opportunity to discuss its contents with you. 

During Episode 32 of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2025 Year-In-Review Report: Global Trends in Biopharma Transactions, covering capital markets, strategic deals, and regional trends.  Market Overview: 2025 marked a clear recovery year for biopharma. Licensing reached record levels, global M&A nearly doubled in value, and capital markets strengthened in the second half as stabilizing rates lifted sentiment. Most notably, China surpassed the U.S. as the leading source of global licensing value. Strategic Transactions: Global licensing totaled roughly $230B across 179 deals, with strength in both early- and late-stage assets. Discovery and preclinical programs made up about 61% of deals, while a late-year rise in Phase 3 transactions pushed average deal sizes to three-year highs. China-based sellers accounted for nearly 50% of global licensing value with larger average deal sizes, while the U.S. led in volume. Absolute upfronts rose about 55% versus 2024. M&A rebounded to approximately $141B across 79 deals, increasingly focused on late-stage and approved assets. Major transactions including Novartis/Avidity, Pfizer/Metsera, and Merck/Cidara drove average deal sizes to multi-year highs. Capital Markets: U.S. public markets outperformed the broader market despite a largely closed IPO window. PIPEs and follow-ons surged, pushing public financings to a three-year high of about $16B, and the number of companies trading below cash fell nearly 60%. In Europe, financing value rose roughly 35% on strong Q4 activity, with investors favoring Phase 1 and Phase 2 programs. Outlook: A selective recovery is underway. Strategic dealmaking remains strong, capital markets are thawing, and high quality assets continue to attract capital, while APAC, especially China and Japan, plays an increasingly central role in global biopharma transactions.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a dynamic phase shaping the industry, marked by scientific advancements, regulatory changes, and strategic shifts within major companies.Teva Pharmaceuticals is making significant strides under the leadership of CEO Richard Francis. The company is transitioning from its traditional focus on generic drugs to a more innovative biopharmaceutical approach. This strategic pivot aims to position Teva alongside industry giants in the biopharma sector, highlighting the increasing importance of innovation over generics in today's competitive landscape.Similarly, Fujifilm is enhancing its competitive edge by capitalizing on its biologics capacity. Rather than pursuing large mergers and acquisitions, Fujifilm is focusing on internal growth, underscoring a broader industry trend where companies are investing in organic growth and technological enhancements to maintain their market positions. This shift reflects a growing recognition of the value of leveraging unique facility designs and capabilities to boost production and efficiency.In regulatory news, the U.S. Food and Drug Administration (FDA) has mandated that pharmaceutical companies like Sanofi, GSK, AstraZeneca, and CSL include warnings about febrile seizures on flu vaccine labels. While these seizures are typically brief and harmless, transparent communication is crucial to maintain patient trust in vaccination programs. This regulatory update exemplifies the FDA's proactive efforts to enhance drug safety communications and address potential adverse effects associated with vaccines.The FDA has also issued untitled letters to Beone and ImmunityBio for promotional materials that potentially violated advertising guidelines. This action underscores the agency's vigilance in ensuring pharmaceutical marketing practices meet required standards of accuracy and transparency.Meanwhile, former Emergent BioSolutions CEO Robert Kramer faces insider trading allegations related to the sale of company shares before public disclosure of contamination issues at a production facility. This legal action brings to light ongoing scrutiny within the industry regarding corporate governance and ethical practices.In terms of advertising spending, AbbVie's Skyrizi topped annual TV ad spending charts for pharmaceuticals, closely followed by J&J's Tremfya. This highlights the continued emphasis on direct-to-consumer advertising as companies compete for market share in therapeutic areas.Internationally, companies like AbbVie are making strategic moves into emerging therapeutic spaces such as bispecific antibodies. AbbVie's recent deal to enter the PD-1xVEGF bispecific space signifies a growing interest in novel therapeutic modalities that offer potential breakthroughs in cancer treatment.At the policy level, former President Donald Trump announced "The Great Healthcare Plan," targeting insurance industry reforms and drug pricing. Although specifics remain sparse, this initiative reflects ongoing political discourse around healthcare affordability—a critical issue shaping industry strategies and public expectations.Turning our attention to Vedanta Biosciences, the company is reallocating resources toward its lead live bacteria cocktail program by significantly reducing its workforce. This move highlights growing interest in microbiome-based therapies as a novel approach to treating diseases by modulating gut microbiota. Vedanta's focus could have substantial implications for future therapeutic options, particularly in immune-related conditions.At the J.P. Morgan Healthcare Conference (JPM26), Chugai Pharmaceutical emphasized enhancing its recognition in the U.S. biopharma sector through new scientific avenues. This strategy underscores the importance of innovation and collaboration for Support the show

Today I'm joined by not one, not two, but three guests with their takes on the biotech year ahead. In December we tasked Labiotech journalists Jules Adam, Roohi Peter, and Willow Shah-Neville with the task of identifying the five biotech players that they thought would be the ones to watch in 2026. Now you can read that article at Labiotech-dot-EU, and we've linked it in the show notes here in your podcast player, too, but on today's episode I'm joined by Jules, Roohi, and Willow who explain a little more about the companies that caught their eye and what might be expected of those companies in the year ahead.15 companies, three journalists, all in one special podcast as we uncover the companies to watch in 2026.1:18     Meet Jules Adam2:30     Abivax4:04     AAVantgarde Bio6:10     Isotope Technologies Munich (ITM)8:16     MaaT Pharma9:55     Novo Nordisk13:15    Meet Willow Shah-Neville14:29    Kardigan18:23    Braveheart Bio21:16    Beam Therapeutics24:34    MindMed27:39    Kailera Therapeutics32:36    Meet Roohi Peter33:30    Aspen Neuroscience34:45    Reunion Neuroscience36:14    MapLight Therapeutiucs37:41    Hope Medicine38:59    RegenxbioInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Keep an eye on these 15 biotech companies in 2026 Biotech in 2025: A retrospective Eight of the biggest immunology and inflammation (I&I) deals in 2025

The McCullough Report with Dr. Peter McCullough – America faces a reckoning as critics expose the biopharmaceutical complex behind pandemic policy, vaccine safety failures, and suppressed treatments. Gene Bailey and Dr. Peter McCullough challenge government and corporate narratives, warn of lingering spike protein risks, and call for reclaiming bodily autonomy, medical truth, and cultural sanity amid a broader war on humanity...

The McCullough Report with Dr. Peter McCullough – America faces a reckoning as critics expose the biopharmaceutical complex behind pandemic policy, vaccine safety failures, and suppressed treatments. Gene Bailey and Dr. Peter McCullough challenge government and corporate narratives, warn of lingering spike protein risks, and call for reclaiming bodily autonomy, medical truth, and cultural sanity amid a broader war on humanity...

“We're not trying to be everything for everyone. Our specialized focus has been very exciting for me.”Franco Negron, CEO of Simtra BioPharma Solutions, has transformed a 65-year sterile manufacturing legacy into an independent CDMO since the company's carve-out from Baxter International (Baxter) in October 2023. Franco has led over $500 million in capital investments to double capacity and create mirrored capabilities across sites in Indiana, US, and Halle/Westfalen, Germany.Franco brings industry experience from Procter & Gamble, Johnson & Johnson, Novartis, and Patheon, which became part of Thermo Fisher Scientific, where he helped shape integrated CDMO strategies.In this PharmaSource podcast, recorded at CPHI 2025, Franco explains how Simtra is navigating supply chain challenges, tariff uncertainties, and injectable manufacturing complexity, from GLP-1s to antibody drug conjugates.Read more.

After a turbulent 2025, the biopharma industry is heading into the new year with major questions still unresolved. A tough biotech investing environment, aggressive direct-to-consumer drug marketing and sweeping U.S. policy changes reshaped the landscape last year. Many of those pressures are expected to persist into 2026, even as early signs point to a thaw in venture capital. At the same time, the industry is testing whether DTC drug sales can meaningfully affect pricing for patients and whether broad manufacturing onshoring goals can realistically apply to advanced therapies like cell and gene treatments and radiopharmaceuticals. In this week’s episode of "The Top Line," Fierce Pharma’s Fraiser Kansteiner sits down with three biopharma CEOs to unpack what defined 2025 and what comes next. He’s joined by Thijs Spoor, CEO of Perspective Therapeutics; Brian Culley, CEO of Lineage Cell Therapeutics; and Rich Daly, CEO of Catalyst Pharmaceuticals. Together, they tackle issues from DTC sales and onshore manufacturing to drug pricing, regulatory uncertainty at the FDA and the broader innovations the leaders are most excited about this year. To learn more about the topics in this episode: 2026 forecast: After a surge of M&A in Q4, will the trend continue? Editor's Corner: Fierce Biotech's 10 most-read stories of 2025 What a year: Here are the stories that captivated our audience in 2025 Editor's Corner: The top 10 Fierce Pharma Marketing stories of 2025 2026 forecast: Pharma clicks with patients as direct sales model shifts marketing strategies See omnystudio.com/listener for privacy information.

If you're a physician with at least 5 years of experience looking for a flexible, non-clinical, part-time medical-legal consulting role… ...Dr. Armin Feldman's Medical Legal Coaching program will guarantee to add $100K in additional income within 12 months without doing any expert witness work. Any doctor in any specialty can do this work. And if you don't reach that number, he'll work with you for free until you do, guaranteed. How can he make such a bold claim? It's simple, he gets results…  Dr. David exceeded his clinical income without sacrificing time in his full-time position. Dr. Anke retired from her practice while generating the same monthly consulting income.  And Dr. Elliott added meaningful consulting work without lowering his clinical income or job satisfaction. So, if you're a physician with 5+ years of experience and you want to find out exactly how to add $100K in additional consulting income in just 12 months, go to arminfeldman.com.                                                          =============== Get the FREE GUIDE to 10 Nonclinical Careers at nonclinicalphysicians.com/freeguide. Get a list of 70 nontraditional jobs at nonclinicalphysicians.com/70jobs.                                                                                                 =============== Pediatric endocrinologist Dr. Nerissa Kreher shares how she moved from clinical research and fellowship training into the biopharma industry, ultimately serving as chief medical officer at multiple companies and founding Pharma Industry MD Coach. With more than 17 years in biotech and pharma, she now combines executive experience with coaching to help physicians understand what industry careers really look like and how to position themselves for those roles. In this presentation, she compares clinical practice with biopharma work, describes what day-to-day life is like on cross-functional teams, and breaks down the main entry points for physicians—clinical development, pharmacovigilance/drug safety, and medical affairs. She also explains which skills transfer well from clinical medicine, how to think about personality fit, and why learning to balance confidence with humility is crucial when interviewing for industry roles. You'll find links mentioned in the episode at nonclinicalphysicians.com/biopharma-industry/

In this episode of Spark Time!, we speak with Øystein Rekdal, co-founder and CEO of Lytix Biopharma, about how the company reimagined host-defense peptides as a new class of oncolytic molecules for cancer immunotherapy.Øystein shares the full arc of Lytix's development, from an academic discovery in Norway to a clinical-stage platform built around locally administered oncolytic molecules designed to activate the immune system where standard treatments fall short. We explore how Lytix isolated and engineered naturally occurring peptides into drug candidates with clinical momentum, and why this approach differs fundamentally from both traditional cytotoxic agents and oncolytic viruses.The conversation dives into how Lytix's lead program induces immunogenic cell death, exposes tumor antigens, and initiates a broad immune response that extends beyond the treated lesion. We also discuss the company's strategic focus on combination and neo-adjuvant settings, its rationale for intratumoral delivery, and how this platform is positioned to address non-responsive solid tumors.A thoughtful discussion for biotech leaders, investors, and partners interested in differentiated immunotherapy platforms and the strategic decisions required to translate novel biology into real clinical relevance.

Breakthrough science has never been stronger — yet patients still miss life-saving therapies.Despite decades of innovation, most precision medicines fail at the last mile of healthcare delivery.The problem isn't discovery. It's how science, capital, and systems are aligned — or not.Possessing elite science is no longer enough to win in the multi-trillion-dollar biopharma ecosystem.As innovation shifts from West to East and from treatment to prevention, leadership teams struggle to bridge scientific depth with incentives, execution, and real-world delivery. Capital follows speed and scale — not intention — and healthcare systems built decades ago are failing to keep up.In this episode, Alasdair Milton, Principal at KPMG, explains where innovation actually breaks — and what must change for cures to reach patients at scale. From diagnostics and data silos to capital allocation and prevention models, this conversation reframes the next decade of precision medicine.

Welcome to another enlightening episode of "The Brand Called You," where host Ashutosh Garg sits down with Justin Byers, Founder and CEO of Axio BioPharma. Axio is a pioneering AI biomanufacturing company, transforming how monoclonal antibodies and biologics are developed and produced by integrating artificial intelligence and machine learning into drug design and manufacturing processes.In this episode, Justin Byers shares his unique journey from scientist to entrepreneur, the inefficiencies he noticed in traditional biomanufacturing, and how Axio BioPharma accelerates drug development timelines, reduces risk, and ensures regulatory compliance—all while respecting data privacy. Discover how cross-functional teams, AI-driven predictive modeling, and federated data systems are creating real impact in healthcare, making treatments more accessible and paving the way for innovation in rare disease therapies.Whether you're interested in biotech innovation, AI applications in healthcare, or the future of drug manufacturing and delivery, this conversation is filled with valuable insights and practical lessons.

As 2025 closes, biopharma and healthcare are learning to live on shifting ground. In this special year-end episode of "The Top Line," Fierce reporters take stock of a year defined by federal research cuts, vaccine policy fights and leadership churn at the FDA, then push the conversation forward into the questions that will shape 2026. The through line is that uncertainty has become an operating environment, and the industry is recalibrating in real time. Fierce Biotech’s Gabrielle Masson, joined by Darren Incorvia, traces how funding decisions can narrow the pipeline years before the consequences are visible. Fierce Pharma’s Fraiser Kansteiner sits down with Angus Liu and Eric Sagonowsky to unpack the new center of gravity inside federal agencies, where vaccine recommendations, review norms and new FDA pilots are colliding with questions about capacity and outside influence. From there, Ben Adams and James Waldron bring the lens to Europe, where Jefferies in London captured a cautiously optimistic market still wrestling with tariffs, pricing pressure and investment hesitation. The episode closes with Fierce Healthcare’s Heather Landi and Paige Minemyer sharing their outlook on 2026, from the fight over ACA subsidies and Medicaid headwinds to the next phase of AI adoption, where the promise is real but the payoff may be slower, messier and more uneven than the hype suggests. To learn more about the topics in this episode: 'Unprecedented turmoil' engulfing FDA threatens public health: mRNA coalition speaks out FDA names Tracy Beth Høeg, fresh from vaccine safety probe, as acting head of drug center A dozen former FDA commissioners blast Prasad's proposed vaccine policy changes In letter to Makary, biotech CEOs push for FDA stability and say volatility threatens US innovation NIH grant cuts have disrupted hundreds of clinical trials, study finds 'Alternative history' of the NIH shows how a 40% budget cut may thwart new medicines House passes healthcare affordability bill without subsidy extension AMA: A look at concentration in commercial insurance, MA markets 2025 Outlook: Hospital finances show signs of stability, but rising costs will be a major headwind See omnystudio.com/listener for privacy information.

Solid tumors represent one of the largest and most challenging areas in cancer treatment. In this interview, GT Biopharma (NASDAQ: GTBP) CEO Michael Breen explains why the company is expanding its platform into solid tumors and how its NK engager technology is designed to activate the body's natural immune response.Breen discusses the science behind GTB-5550, why B7H3 is a compelling target across many solid tumors, and how preclinical results support the company's next steps. He also outlines key milestones from 2025 and what investors should watch as GT Biopharma moves toward clinical trials and data readouts in 2026.Learn more about GT Biopharma: https://www.gtbiopharma.com/Watch the full YouTube interview here: https://www.youtube.com/watch?v=I7-Vd8PO8L0And follow us to stay updated: https://www.youtube.com/@GlobalOneMedia

HSBC Innovations is the global bank's financing arm for American and European startups, especially in the healthcare and life sciences industries. The bank's semi-annual Venture Healthcare Reports document trends in the investment market.Key Tech's Andy Rogers welcomes the report's author, HSBC Innovation Managing Director Jon Norris in Episode 43 of the MedTech Speed to Data podcast.Need to know·       Four core market segments — HSBC Innovation's Venture Healthcare Reports cover investments and exits in Biopharma, Dx/Tools, Med Device, and Healthtech.·       Sourcing investment data — Norris enriches Pitchbook data with additional structure and analyses, making the report more relevant to these market segments.·       Sourcing exit data — Norris supplements media and industry publications with market research and conversations with industry leaders.·       An investment data tapestry — The reports provide “an honest picture of what's going on in the market” so investors and innovators alike “can make targeted smart decisions.”The nitty-grittyAndy and Norris discuss the investment market's recent history before exploring drivers of today's investment headwinds.“2021 was a record-setting year,” Norris recalls. “Every record that could be set for deals and dollars was set across all the sectors.” Things changed in 2022 as new BioTech IPOs struggled, prompting investment reprioritizations.“VCs had done all these… frothy valuations,” Norris says. “They had to go back and look at their own portfolios and say, does this company have enough capital? How do you want to put money to work?”Investments rebounded in 2024, but not the number of deals. Investors poured money into their existing portfolios to boost their exit chances, resulting in today's nine-figure megadeals.“Basically, they're smooshing two rounds together and extending the investors coming in to support that round,” Norris says.Headwinds stiffened in 2025 as tariffs, a more litigious competitive space, and other factors amplified business uncertainty.Norris attributes this progression to the psychology of venture capital. “When you think about what makes these folks tick,” Norris explains, “they want to continue to raise new venture funds because they get paid management fees. But in order to raise their new venture funds, they have to show their investors that they've actually gotten returns.”That means reaching an acquisition or IPO. “They're very focused on getting to exit right now. That's why they're so focused on their existing portfolio. And because of that, they haven't been doing as many new investments.”New investments still happen, of course, but the criteria have changed. “While the dollars are actually up in some of these sectors, especially Med Device,” Norris says, “you're seeing that being put to work on later-stage deals because they'd rather get a shorter time to exit.”Data that made the difference:Norris' insights from the HSBC Venture Healthcare Report let him advise startups fighting today's investment headwinds.Adopt a megaround mentality. “Series B has been extremely difficult,” Norris says. “[Raising] sub two million, that's one thing. But if you're looking to raise five million, it's almost better to raise twelve.”Find investors outside the mainstream. “Traditional venture investors don't want to write small checks.” Norris sees angel groups, innovation centers, and other small investors funding these early rounds.Explore acquisition exits, but be careful. “On the device side, most of the corporates have been pretty darn active,” Norris says. However, some litigate to block emerging competition, especially in the Dx/Tools sector. Norris' recommends researching potential acquirers before taking meetings.Download the HSBC Venture Healthcare Report for Norris' complete analysis, and watch the video below for insights into the Medical Device and Dx/Tools sectors, AI's role in MedTech, and more.

The FDA Group's Nick Capman sits down with Chris Masterson, Senior Vice President of Quality and Chief Quality Officer at Tolmar, for a wide-ranging conversation about how to create and sustain a quality-centric culture that drives compliance, operational excellence, and long-term resilience in the biopharmaceutical industry. A microbiologist by training with more than 35 years of BioPharma leadership experience, Chris has led global quality organizations at Ipsen, Cubist (Merck), and now Tolmar, as well as his own consultancy. Across the U.S., Europe, and Asia, he has managed large CMO networks, established inspection-readiness programs, and led cultural change within complex, matrixed organizations.Nick and Chris explore what truly defines a quality-centric culture, how leadership and accountability shape it, and the practical, long-term steps required to sustain it.In this conversation, Chris shares insights on:What “quality culture” really means—and how to make it visible at every level of an organization.The leadership behaviors that create alignment and consistency across global teams.How to embed compliance and continuous improvement into daily operations.Managing uncertainty, pressure, and change without losing focus on the patient.Practical methods for measuring and improving quality culture over time.Why humility and transparency are non-negotiable for sustainable performance.About The FDA GroupThe FDA Group helps life science organizations rapidly access the industry's best consultants, contractors, and candidates. Our resources assist in every stage of the product lifecycle—from clinical development to commercialization—with a focus on staff augmentation, auditing, remediation, QMS, and other specialized project work in Quality Assurance, Regulatory Affairs, and Clinical Operations. Learn more: https://www.thefdagroup.com/

Uncertainty reigned early this year with the inauguration of President Donald Trump and his threats to impose tariffs and slash prescription drug prices. But as players in the biopharma industry have gotten a better handle on the impact of these measures and the overall investment landscape, valuations have become more predictable and dealmakers have focused on larger, lower-risk acquisitions. The recent trends bode well for the business development landscape in 2026 and beyond. In this week’s episode of “The Top Line,” Arda Ural, EY Americas life sciences sector leader, joins Fierce Pharma’s Kevin Dunleavy to discuss the dealmaking landscape in the biopharma industry. They dig into the Federal Trade Commission’s scrutiny of M&A transactions, revitalized therapeutic areas, artificial intelligence investment and the emergence of China as an innovation powerhouse. To learn more about the topics in this episode: 2025 M&A up in value and deal count after year of 'conservatism and recovery': Leerink Partners After a 'reset' year for M&A, expect bigger deals in 2025: reports See omnystudio.com/listener for privacy information.

Published Dec. 4, 2025In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss Protecting Access to Medicare Act (PAMA) reform and the first reported death from alpha-gal syndrome. Later, Dr. Pritt welcomes Chris Garcia, M.D., Mayo Clinic Laboratories' chief digital innovation officer and medical director of BioPharma Diagnostics, to explore how biopharma diagnostics advance research and development. PAMA reform update (00:33): Get the latest on where reform to PAMA stands following the federal government's reopening.Alpha-gal syndrome case (03:22): Learn about the first known death from alpha-gal syndrome and diagnostic testing for this tick-bite-triggered red meat allergy.Biopharma's role in research and development (07:52): Discover how biopharma diagnostics fuel innovation and how digital tools are expanding its future impact.  Note: Information in this post was accurate at the time of its posting.ResourcesBioPharma Diagnostics: Connecting pharma and biotechTick-borne disease: An expanding geographic threat

Uttam Patil of ABVC BioPharma, Greg Smitherman & James McCormick of CloudaStructure, and Corey Perlman of Impact Social MediaDr. Uttam Patil of ABVC BioPharma discusses their trans-Pacific biotech platform that connects U.S. and Asian innovation with clinical development excellence. Also, Greg Smitherman & James McCormick of CloudaStructure share the advancements in their AI surveillance technology. Corey Perlman of Impact Social Media shows how AI is impacting the music industry. 

In this conversation, Vanessa Delgado discusses the complexities of multi-family investments, emphasizing that it is not a quick scheme but a serious business requiring effective management of teams and stakeholders. She highlights the importance of understanding the various players involved in real estate, including investors, regulatory agencies, and customers, to successfully manage and deliver value in the industry.   Professional Real Estate Investors - How we can help you: Investor Fuel Mastermind:  Learn more about the Investor Fuel Mastermind, including 100% deal financing, massive discounts from vendors and sponsors you're already using, our world class community of over 150 members, and SO much more here: http://www.investorfuel.com/apply   Investor Machine Marketing Partnership:  Are you looking for consistent, high quality lead generation? Investor Machine is America's #1 lead generation service professional investors. Investor Machine provides true 'white glove' support to help you build the perfect marketing plan, then we'll execute it for you…talking and working together on an ongoing basis to help you hit YOUR goals! Learn more here: http://www.investormachine.com   Coaching with Mike Hambright:  Interested in 1 on 1 coaching with Mike Hambright? Mike coaches entrepreneurs looking to level up, build coaching or service based businesses (Mike runs multiple 7 and 8 figure a year businesses), building a coaching program and more. Learn more here: https://investorfuel.com/coachingwithmike   Attend a Vacation/Mastermind Retreat with Mike Hambright: Interested in joining a "mini-mastermind" with Mike and his private clients on an upcoming "Retreat", either at locations like Cabo San Lucas, Napa, Park City ski trip, Yellowstone, or even at Mike's East Texas "Big H Ranch"? Learn more here: http://www.investorfuel.com/retreat   Property Insurance: Join the largest and most investor friendly property insurance provider in 2 minutes. Free to join, and insure all your flips and rentals within minutes! There is NO easier insurance provider on the planet (turn insurance on or off in 1 minute without talking to anyone!), and there's no 15-30% agent mark up through this platform!  Register here: https://myinvestorinsurance.com/   New Real Estate Investors - How we can work together: Investor Fuel Club (Coaching and Deal Partner Community): Looking to kickstart your real estate investing career? Join our one of a kind Coaching Community, Investor Fuel Club, where you'll get trained by some of the best real estate investors in America, and partner with them on deals! You don't need $ for deals…we'll partner with you and hold your hand along the way! Learn More here: http://www.investorfuel.com/club   —--------------------

In this episode of The Top Line, Fierce’s Chris Hayden speaks with Foresight Diagnostics co-founders Dr. Jake Chabon and Dr. Max Diehn about how their company is delivering the next generation of minimal residual disease (MRD) detection in cancer care. Born from research at Stanford University, Foresight’s PhasED-Seq technology delivers ultra-sensitive detection—down to parts per ten million—enabling clinicians to identify microscopic traces of cancer that traditional imaging misses. The discussion explores how Foresight’s MRD platform, CLARITY, can have the ability to support more confident decision-making, from determining curative success in early-stage cancers to guiding consolidation treatment in lymphoma. Chabon and Diehn highlight the company’s biopharma collaborations, clinical trial integration, and evidence-driven approach to guideline inclusion. They also look ahead to a future where MRD testing becomes central to oncology surveillance, accelerating therapy approvals and complementing genomic and digital pathology tools to advance precision medicine.See omnystudio.com/listener for privacy information.

In this week’s episode of "The Top Line," we take a deep dive into the top-line performance of the biopharma industry in the third quarter. After a slow start to the year, U.S. drugmakers in particular have recovered, led by Eli Lilly. We examine which companies are hot and which are not. We also look at trends that emerged in the third quarter, such as the shortfall in vaccine sales, especially in the U.S., and companies’ sales projections for the rest of the year. Fierce Pharma’s Kevin Dunleavy and Eric Sagonowsky discuss their observations from the third quarter and put the industry’s performance in perspective compared with previous quarters. They also examine the biopharma outlook for the fourth quarter. To learn more about the topics in this episode: Q1 biopharma layoff trends, plus expectations for Q2 7 top pharmas posted revenue declines in Q1. The common thread? All are US firms Several US pharma giants stage Q2 sales turnaround after subpar results earlier in year See omnystudio.com/listener for privacy information.

A breakthrough that could reshape cancer treatment.GT Biopharma (NASDAQ: GTBP) is advancing its next generation TriKE® platform, an innovative immunotherapy that activates the body's own natural killer cells to identify and destroy cancer. In this interview, Executive Chairman & CEO Michael Breen discusses the company's latest clinical progress and the potential of its lead drug candidate, GTB-3650.He also shares insights into the science behind TriKE®, the company's pipeline for solid tumors and autoimmune diseases, and its mission to develop more humane cancer therapies that bring real hope to patients worldwide.Learn more about GT Biopharma: https://www.gtbiopharma.com/Watch the full YouTube interview here: https://youtu.be/jduKYNKHMIYAnd follow us to stay updated: https://www.youtube.com/@GlobalOneMedia

A breakthrough that could reshape cancer treatment.GT Biopharma (NASDAQ: GTBP) is advancing its next generation TriKE® platform, an innovative immunotherapy that activates the body's own natural killer cells to identify and destroy cancer. In this interview, Executive Chairman & CEO Michael Breen discusses the company's latest clinical progress and the potential of its lead drug candidate, GTB-3650.He also shares insights into the science behind TriKE®, the company's pipeline for solid tumors and autoimmune diseases, and its mission to develop more humane cancer therapies that bring real hope to patients worldwide.Learn more about GT Biopharma: https://www.gtbiopharma.com/Watch the full YouTube interview here: https://youtu.be/jduKYNKHMIYAnd follow us to stay updated: https://www.youtube.com/@GlobalOneMedia

Crypto News: Scott Bessent says the US Treasury and IRS approve staking in crypto ETFs. The Senate Agriculture committee has released its long-awaited bipartisan crypto market structure discussion draft.Brought to you by

Remember - all the tools I use will have Black Friday sales. ADD THEM TO YOUR HOLIDAY WISH LIST. Get your family and friends to gift you these tools for the holidays instead of buying you underwear and sock. Here are the links to all the sales: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TRENDSPIDER - HUGE SALE ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Our U.S. Biotech and Biopharma analysts Sean Laaman and Terence Flynn discuss the latest developments that could be positioning the healthcare sector for strong outperformance.Read more insights from Morgan Stanley.----- Transcript -----Sean Laaman: Welcome to Thoughts on the Market. I'm Sean Laaman, Morgan Stanley's U.S. Small and Mid-Cap Biotech Analyst. Terence Flynn: And I'm Terence Flynn, Morgan Stanley's U.S. Biopharma Analyst. Sean Laaman: Today, we'll discuss how a rally in the healthcare sector is being driven by more favorable macro conditions. It's Tuesday, October 28th at 10am in New York. So, Terence, healthcare has lagged the broader market year-to-date, and valuations have been near historical lows. But recent weeks show strengthening performance. Policy headwinds have been front and center.What's changed in the regulatory environment and how is the biopharma sector adapting to these pricing and tariff dynamics? Terence Flynn: Sean, as you know, with many other sectors, tariffs were initially a focus earlier this year. But a number of companies in our space have subsequently announced significant U.S. manufacturing investments to reshore supply chains. And hence, the market's less focused on tariffs in our space right now. But the other policy dynamic and focus is what's called Most Favored Nation or MFN drug pricing. Now, this is where the President's been focused on aligning U.S. drug prices with those in other developed countries. And recently we've seen several companies announce agreements with the administration along these lines, which importantly has provided investors with more visibility here. And we're watching to see if additional agreements get announced. Sean Laaman: Got it. Another hurdle for Large-cap biopharma is a looming expiration of patents with [$]177 billion exposed by 2030. How is this shaping M&A trends and strategic priorities? Terence Flynn: For sure. I mean, as you know, Sean, patent expiry is our normal part of the life cycle of drug development. Every company goes through this at some point, but this does put the focus on company's internal pipelines to continue to progress while also being able to access external innovation via M&A. Recently we have started to see a pickup in deal activity, which could bode well for performance in SMID-cap biotech. Sean Laaman: At the same time, you believe relative valuations look compelling for Large-cap biopharma. Where are valuations versus where they've been historically? What's driving this and how should investors think about positioning? Terence Flynn: Absolutely. Look, on a price to earnings multiple, the sector's trading at about a 30 percent discount to the S&P 500 right now. Now that's in line with prior periods of policy uncertainty. But as policy visibility improves, we expect the focus will shift back to fundamentals. Now, positioning to me still feels light here, given some of the patent cliff dynamics we just discussed. Now, Sean, with the Fed moving toward rate cuts, how do you see this impacting your sector on the biotech side? Sean Laaman: Well, Terence, particularly in my space, which is Small- and Mid-cap biotech companies, they're typically capital consumers are not capital producers. They're particularly sensitive to the current rate environment.Therefore, they're sensitive to spending on pipeline. They're sensitive to M&A. So, as rates come down, we expect more spending on pipeline and more M&A activity, which is generally positive for the sector. Looking forward, biotech sector is generally the best performing sector on a six-to-12-month timeframe post the first rate cut. Terence Flynn: Great. You've also talked about this SMID to Big thesis on the biotech side. Can you explain what's driving that? Sean Laaman: Sure Terence. There's three pieces to the SMID to Big thematic. So, we in SMID-cap biotech, we cover 80 to 90 companies. About a third of those are newly, kind of profitable companies. Those companies are turning from being capital consumers to capital producers. We see about $15 billion of cash on balance sheets for 2025, going to north of 130 billion by 2030. That's the first piece. The second piece is due to regulatory uncertainty at the USFDA. We're seeing more attractive valuations amongst clinical stage names. That's the second piece. And third piece relates to your coverage, Terence. I refer back to that [$]177 billion of LOE. So, we expect generally that M&A activity will be quite high amongst our sector. Terence Flynn: And let's not forget about AI, which has implications across the healthcare space. How much is this changing the dynamic in biotech, Sean? Sean Laaman: It is changing, but we're really at the beginning. I think there's three things to think about. The first one is faster trial recruitment. The second one is faster regulatory submissions. And the third one, which is the most interesting, but we're really at the beginning of, is faster time to appropriately targeted molecules. Terence Flynn: Great. And maybe lastly, what are the key risks and catalysts for SMID-cap biotech in the current environment? Sean Laaman: As always, we're focused on pipeline failures in terms of risk. Secondly, in terms of risk, we're looking at regulatory risk at the FDA. And thirdly, we're looking at the rise in China biotech and the competitive dynamic there.Whether you're watching large cap biopharma, M&A moves, or the rise of cash-rich, SMID-cap biotechs, the healthcare sector setup is unlike anything we've seen in years.Terence, thanks for speaking with me. Terence Flynn: Always a pleasure to be on the show. Thanks for having me, Sean. Sean Laaman: And thanks for listening. If you enjoy Thoughts on the Market, please leave us a review wherever you listen and share the podcast with a friend or colleague today.

Diane King Hall and Nicole Petallides discuss markets at all-time highs. Also topping new heights: Micron (MU), following a bullish price target hike from the analyst at Citi. Diane points to the company's role in the memory space and expected price increases as a catalyst for the company. Meanwhile, Keurig Dr Pepper (KDP) pops after a "perking up" in its earnings, including gains in U.S. coffee sales. Novartis (NVS) announces a deal to acquire Avidity Biosciences for $12B.======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-...Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-...Watch on Sling - https://watch.sling.com/1/asset/19192...Watch on Vizio - https://www.vizio.com/en/watchfreeplu...Watch on DistroTV - https://www.distro.tv/live/schwab-net...Follow us on X – / schwabnetwork Follow us on Facebook – / schwabnetwork Follow us on LinkedIn - / schwab-network About Schwab Network - https://schwabnetwork.com/about

Synopsis: Host Rahul Chaturvedi sits down with Geoffrey Duyk, Chief Executive Officer of Grove Biopharma, for a wide-ranging conversation on navigating today's biotech macro headwinds and building companies that can translate breakthrough science into real patient impact. Dr. Duyk traces his journey from Harvard/Millennium/Exelixis operator to TPG investor and back to company creation, explaining how board dynamics, capital cycles, and policy shifts shape execution. They dig into why this cycle feels uniquely tough—patent cliffs, reimbursement uncertainty, NIH pressures—and who funds innovation in the meantime. Duyk outlines root causes of R&D inefficiency (misaligned capital vs. 20-year timelines, shaky preclinical predictability, costly trials, underused real-world data) and makes the case for rebuilding public trust and STEM education. Then, a deep dive on Grove Biopharma: precision polymer science that creates antibody-like, fully synthetic, cell-permeable protein mimetics to tackle historically “intractable” intracellular protein–protein interactions. Duyk shares design principles, why modular/orthogonal chemistry matters, predictable pharmacology, and lessons from fundraising and board management—plus why he's helping grow a Chicago-centered biotech ecosystem. Biography: Geoffrey M. Duyk, M.D., Ph.D. is the Chief Executive Officer of Grove Biopharma. Dr. Duyk has spent 30 years in the biotechnology industry as an entrepreneur, executive, and investor. Most recently, he was the Managing Partner at Circularis Partners, an investment firm he co-founded, focused on advancing the circular economy and promoting sustainability. Prior to that, Dr. Duyk was Managing Director and Partner at TPG Alternative & Renewable Technologies (ART)/TPG Biotechnology. Before joining TPG, Dr. Duyk served as a board member and President of R&D at Exelixis and was one of the founding scientific staff members at Millennium Pharmaceuticals, where he served as Vice President of Genomics. Earlier in his career, Dr. Duyk was an Assistant Professor in the Department of Genetics at Harvard Medical School (HMS) and an Assistant Investigator at the Howard Hughes Medical Institute (HHMI). While at HMS, he served as a co–principal investigator in the Cooperative Human Linkage Center, which was funded by the National Institutes of Health (NIH). Dr. Duyk is a trustee of Case Western Reserve University, where he serves on the executive committee. He previously served on the Board of Trustees of Wesleyan University and the Board of Directors of the Moffitt Cancer Center. He currently serves on the IR&E (Institutional Research and Evaluation) Committee at Moffitt, a key component of its External Advisory Committee (EAC). He was also a member of the Board of Directors of the American Society of Human Genetics (ASHG), and served as its treasurer. He is a member of the Life Sciences Advisory Board at Innovatus Capital Partners and the Scientific Advisory Board (SAB) for Lawrence Berkeley National Laboratory (DOE). Dr. Duyk previously served on the board of the Jackson Laboratory and on numerous NIH advisory committees. He is currently a Senior Advisor at Qiming Venture Partners (USA) and serves on the boards of Enno DC, Oobli, and Melanyze Dr. Duyk earned both his M.D. and Ph.D. from Case Western Reserve University and completed his medical and fellowship training at the University of California, San Francisco (UCSF). While at UCSF, he was a Lucille P. Markey Fellow and an HHMI postdoctoral fellow. He is a fellow of the American Association for the Advancement of Science.

During Episode 30 of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2025 Q3 Report: Global Trends in Biopharma Transactions Report, covering capital markets, strategic deals, and regional trends.  Market Overview: Q3 signaled a cautious biotech recovery. Valuations rebounded, the XBI topped 100 for the first time since 2022, and the number of companies trading below cash hit multi-year lows. Investor sentiment shifted from survival to selective growth amid improving macro stability and risk tolerance. Strategic Transactions: Licensing held steady with renewed interest in early-stage programs and back-loaded structures (upfronts

During Episode 31 of Biotalk, Geoff Meyerson, CEO of Locust Walk, explores Asia-Pacific biotech momentum across China, Japan, and Korea, as featured in our 2025 Q3 Report: Global Trends in Biopharma Transactions Report. China: Led globally in licensing ($34.2B, 48% share), with venture financing up nearly 4x. Investor confidence rose alongside strong public market gains and creative deal structures. Japan: Shifted toward early-stage, non-core areas like dermatology and metabolic disease. Licensing values fell, but venture funding spiked 300% as the Nikkei hit record highs. Korea: Normalized after Q2 strength; modest licensing and market gains amid continued caution. Regional Takeaway: Asia-Pacific remains a bright spot—China driving deal value, Japan diversifying early innovation, and Korea stabilizing. The region reflects a measured but sustained re-engagement in biotech capital and partnerships. Listen now to gain insights into the evolving global biopharma landscape, explore our report, and we welcome the opportunity to discuss its contents with you. 

GT Biopharma (NASDAQ: GTBP) is pioneering a new era in cancer treatment: one that replaces cutting, burning, and poisoning with precision, safety, and the power of the body's own immune system.In this interview, Executive Chairman & CEO Michael Breen and Consulting Senior Medical Director Dr. Jeffrey Miller discuss how GT Biopharma's TriKE® technology harnesses natural killer (NK) cells to target and destroy cancer cells, offering a more humane alternative to traditional therapies. They talk about the science behind their platform, the progress of ongoing Phase 1 clinical trials for blood cancer, upcoming FDA filings for solid tumors, and how next-generation nanobody and camelid technology is advancing efficacy and safety.Discover why GT Biopharma's platform represents one of the most promising innovations in immunotherapy and why investors are watching closely as key data milestones approach.Learn more about GT Biopharma: https://www.gtbiopharma.com/Watch the full YouTube interview here: https://youtu.be/he9i0aJQ2JMAnd follow us to stay updated: https://www.youtube.com/@GlobalOneMedia

GT Biopharma (NASDAQ: GTBP) is pioneering a new era in cancer treatment: one that replaces cutting, burning, and poisoning with precision, safety, and the power of the body's own immune system.In this interview, Executive Chairman & CEO Michael Breen and Consulting Senior Medical Director Dr. Jeffrey Miller discuss how GT Biopharma's TriKE® technology harnesses natural killer (NK) cells to target and destroy cancer cells, offering a more humane alternative to traditional therapies. They talk about the science behind their platform, the progress of ongoing Phase 1 clinical trials for blood cancer, upcoming FDA filings for solid tumors, and how next-generation nanobody and camelid technology is advancing efficacy and safety.Discover why GT Biopharma's platform represents one of the most promising innovations in immunotherapy and why investors are watching closely as key data milestones approach.Learn more about GT Biopharma: https://www.gtbiopharma.com/Watch the full YouTube interview here: https://youtu.be/he9i0aJQ2JMAnd follow us to stay updated: https://www.youtube.com/@GlobalOneMedia

Sully, Mike Costa and Mary Burt-Godwin interview Dr. Uttam Patil of ABVC BioPharma, Ardes Johnson of NeoVolta, and CEO coach and college professor Dan Negroni.

Hamid Ghanadan, CEO of LINUS, discusses the findings of the company's recent state-of-the-science research, a semiannual survey that tracks sentiment and confidence within the life sciences. Notably, a growing gap in optimism exists between academic and biopharma scientists.  As a result, academics are seeking partnerships at a new level due to economic pressures from grant cancellations, the need for multidisciplinary collaboration to solve complex problems, and the desire for a stronger collective voice. AI was identified as the top priority for academia and biopharma, as is the need to improve communication with the public about scientific discoveries and medical advancements. Hamid explains, "We started the state-of-the-science research four years ago, so this is the eighth time that we've done it. And what we're really doing is measuring consumer confidence within the life sciences. So we track sentiment, we track funding, we track barriers and opportunities, as well as purchase intentions. And we do it every six months for the coming six months of the year."   "So here you have to take into consideration that we talk to scientists globally in this survey, and we talk to them from a variety of different settings and environments. So while about half of our respondents are from academic institutions around the world, the other half are in a variety of industries, mostly biopharma. And we see here that there's a shift, there's a difference in sentiment and in optimism, in outlook, in interest in science, in the applicability of science, and how these different groups are managing it. As you can imagine, the academics are feeling a lot more pressure."   "The consumer sentiment is lower, and there's definitely more fear in that cohort of scientists. Biopharma is actually surprisingly more resilient, more forward-looking. So on the biopharma side, what we're seeing is that there's actually surprising resilience and there's forward-looking intentions. And we see that scientists are actually looking forward to applying new techniques and new technologies that are coming online, and they have more confidence in their ability to make progress for the second half of 2025."   #LINUSGroup #Lifesciences #Healthcare #AIHealthcare #Stategy #Scientists #AI #MedAI thelinusgroup.com Listen to the podcast here

Hamid Ghanadan, CEO of LINUS, discusses the findings of the company's recent state-of-the-science research, a semiannual survey that tracks sentiment and confidence within the life sciences. Notably, a growing gap in optimism exists between academic and biopharma scientists.  As a result, academics are seeking partnerships at a new level due to economic pressures from grant cancellations, the need for multidisciplinary collaboration to solve complex problems, and the desire for a stronger collective voice. AI was identified as the top priority for academia and biopharma, as is the need to improve communication with the public about scientific discoveries and medical advancements. Hamid explains, "We started the state-of-the-science research four years ago, so this is the eighth time that we've done it. And what we're really doing is measuring consumer confidence within the life sciences. So we track sentiment, we track funding, we track barriers and opportunities, as well as purchase intentions. And we do it every six months for the coming six months of the year."   "So here you have to take into consideration that we talk to scientists globally in this survey, and we talk to them from a variety of different settings and environments. So while about half of our respondents are from academic institutions around the world, the other half are in a variety of industries, mostly biopharma. And we see here that there's a shift, there's a difference in sentiment and in optimism, in outlook, in interest in science, in the applicability of science, and how these different groups are managing it. As you can imagine, the academics are feeling a lot more pressure."   "The consumer sentiment is lower, and there's definitely more fear in that cohort of scientists. Biopharma is actually surprisingly more resilient, more forward-looking. So on the biopharma side, what we're seeing is that there's actually surprising resilience and there's forward-looking intentions. And we see that scientists are actually looking forward to applying new techniques and new technologies that are coming online, and they have more confidence in their ability to make progress for the second half of 2025."   #LINUSGroup #Lifesciences #Healthcare #AIHealthcare #Stategy #Scientists #AI #MedAI thelinusgroup.com Download the transcript here

What if cancer treatment could harness the body's own immune system instead of relying on surgery, radiation, or chemotherapy? GT Biopharma (NASDAQ: GTBP) is developing its TriKE® platform, a novel NK cell engager designed to activate natural killer cells to seek out and destroy cancer.In this interview, Executive Chairman & CEO Michael Breen discusses the company's origins, the science behind its technology, and its progress in clinical trials for acute myeloid leukemia. He also outlines GT Biopharma's plans to expand into solid tumors and autoimmune diseases, highlighting the commercial potential and challenges ahead. Watch the full interview to learn how the company is advancing immunotherapy in a new direction.Learn more about GT Biopharma: https://www.gtbiopharma.com/ Watch the full YouTube interview here: https://youtu.be/Z9tNa4JTELwAnd follow us to stay updated: https://www.youtube.com/@GlobalOneMedia?sub_confirmation=1

What if cancer treatment could harness the body's own immune system instead of relying on surgery, radiation, or chemotherapy? GT Biopharma (NASDAQ: GTBP) is developing its TriKE® platform, a novel NK cell engager designed to activate natural killer cells to seek out and destroy cancer.In this interview, Executive Chairman & CEO Michael Breen discusses the company's origins, the science behind its technology, and its progress in clinical trials for acute myeloid leukemia. He also outlines GT Biopharma's plans to expand into solid tumors and autoimmune diseases, highlighting the commercial potential and challenges ahead. Watch the full interview to learn how the company is advancing immunotherapy in a new direction.Learn more about GT Biopharma: https://www.gtbiopharma.com/ Watch the full YouTube interview here: https://youtu.be/Z9tNa4JTELwAnd follow us to stay updated: https://www.youtube.com/@GlobalOneMedia?sub_confirmation=1

What if biotech teams could automate the most information-intensive parts of bringing a drug to market? In this episode of Data in Biotech, host Ross Katz speaks with Convoke co-founders Alex Telford and Maged Ahmed about building an AI-native knowledge acquisition and curation system for biopharma. Learn how they're transforming clinical research, regulatory writing, and competitive intelligence using LLMs, semantic search, and scalable data infrastructure. ​​What You'll Learn in This Episode: >> How Convoke unifies public and private biotech data into a single workspace for smarter decision-making >> Why structured outputs and semantic layers are key to high-quality AI-driven insights >> Real-world use cases including clinical trial design, competitive landscape analysis, and regulatory documentation >> How feedback loops and model evaluations drive product reliability and user trust >> The future of AI in biotech: continuous decision-making and multimodal intelligence Meet Our Guests Alex Telford is Co-Founder and CEO of Convoke, an AI-native OS transforming drug development workflows. His background in life sciences consulting drives his mission to unify data and streamline outputs like clinical documents and regulatory submissions. Maged Ahmed is Co-Founder of Convoke and a former AI lead at Applied Intuition. He brings deep data infrastructure expertise to biotech, aiming to reduce friction in regulated environments by automating knowledge generation. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Alex Telford  on LinkedIn Connect with Maged Ahmed on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

No guest this week, so it's time for our first Ask Me Anything (AMA) episode since 2019! Past guests and pals peppered me with questions about the podcast, my reading habits, menswear aesthetics, mental health, comics, hair care, keeping a journal, work/life balance or lack thereof, the one episode I think people are sleeping on, Star Trek vs. Star Wars, the superpower I wish I had, and a lot more. I dish some pod-secrets, talk about the episodes that will never air, and tell you where I buy my underwear, so go listen! Follow me on Bluesky and Instagram • More info at our site • Support The Virtual Memories Show via Stripe, Patreon, or Paypal, and subscribe to our e-newsletter

The McCullough Report with Dr. Peter McCullough – USA Facts reinterprets CDC data to reveal that 81% of Americans received at least one COVID-19 shot, yet only 70% achieved full vaccination. Disparities persist across demographics, with low coverage in infants. Critics lambaste CDC's transparency and the FDA's new framework. With booster uptake below 15%, concerns arise about pharma influence and public health policy...